Impact of Dalbavancin, Oritavancin for ABSSSI on Healthcare Costs
This article is written live from ID Week 2017 Annual Meeting in San Diego, CA. MPR will be reporting news on the latest findings from leading experts in infectious diseases. Check back for more news from IDWeek 2017.
SAN DIEGO—The high cost of dalbavancin and oritavancin might be largely offset by potential cost savings associated with earlier patient discharges, according to a small, retrospective, single-hospital chart review of patients with a primary diagnosis of acute bacterial skin and skin structure infections (ABSSSI) during 2015 and 2016, presented at IDWeek 2017.
"Inpatient administration of dalbavancin or oritavancin was predicted to result in a small loss or a small financial gain for our hospital, respectively," reported lead study author Christina Koutsari, PharmD, PhD, of Abbott Northwestern Hospital in Minneapolis, MN. "Careful selection of candidates for inpatient use of dalbavancin and oritavancin can benefit certain patients without negatively impacting ANW pharmacy budget."
Cost-analysis was performed to identify potential cost savings with use of dalbavancin or oritavancin instead of the traditional antibiotic therapy, Dr. Koutsari reported.
“Eight patients met the selection criteria with the majority being intravenous drug users,” she said. “Actual length of stay of candidates for dalbavancin or oritavancin was 4.3±2.8 days. Predicted length of hospital stay if dalbavancin or oritavancin were used was 3.0±1.9 days (P=0.03 vs. actual length of stay).”
The authors concluded that dalbavancin or oritavancin "may have prevented four remissions, two peripherally inserted catheter insertions, and use of daptomycin in one patients."
Dalbavancin or oritavancin “may have been used in a small proportion of admissions (3%) with skin and soft tissue infection as primary diagnosis,” Dr. Koutsari noted.
For continuous infectious disease news coverage from the IDWeek 2017, check back to MPR's IDWeek page for the latest updates.
Koutsari C, Gens K, Holt J. Evaluation of dalbavancin and oritavancin as cost-effective treatments of acute bacterial skin and skin structure infections in hospitalized patients. Poster presented at IDWeek; October 4–8, 2017; San Diego, CA. http://www.idweek.org